# 01 Sequencing and Microarray Facility

> **NIH NIH P30** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2022 · $767,537

## Abstract

PROJECT SUMMARY: THE SEQUENCING AND MICROARRAY FACILITY (SMF)
The mission of the Sequencing and Microarray Facility (SMF) is to use state-of-the-art instrumentation and
innovative technical expertise to provide investigators with the highest quality genomic data from a
comprehensive range of genomic services, which include Illumina platform-based next-generation sequencing
(NGS) services (whole genome, whole exome, RNA-Seq, ChIP-Seq, and single-cell analysis), Sanger- and
Illumina-based gene resequencing, and microarray platforms (gene expression, microRNA, methylation, single-
nucleotide polymorphism, and copy number analyses). For these services, the SMF innovates and develops
customized protocols, as needed, to enable investigators to obtain reliable genomic data on specimens that are
commonly found in cancer center tissue banks such as FFPE tissues, serum, plasma, and urine, the analytes
from which are often of low quality and/or quantity. Demand for SMF's NGS service has increased 1374% over
the prior grant cycle.
The SMF director is Dr. Vicki Huff, co-directors are Drs. Sharon Dent and Nicholas Navin, and the Facility
Manager is Ms. Erika Thompson. Instrumentation includes two NovaSeqs, a HighSeq4000, two HiSeq2000s,
a NextSeq500, a MiSeq, two ABI 3730s, a digital droplet PCR System, a Fluidigm C1 Single-Cell Auto Prep and
EVOS FL Auto Imaging Systems, a Nanostring nCounter MAX Analysis System, a 10X Genomics Chromium
System, an Affymetrix Fluidics Station, and two robotic workstations (Agilent Bravo and Eppendorf epMotion
5075 TMX). Many of these were purchased using the $3,171,019 the institution has provided the SMF for
equipment since 2013. One of the NovaSeq6000s was purchased with an NIH S10 HEI grant award.
The SMF supported the research of 482 MD Anderson investigators, 361 of whom are CCSG program members
representing all 16 CCSG programs. In the past grant cycle, SMF contributed to 649 publications, 78% of which
were published in journals with IF >5 and 29% of which were published in journals with IF >10. Chargeback fees
provided 93% of the SMF budget of $7,138,252. CCSG support was 6.8% ($486,766). Because 93% of the
samples processed by the SMF were from peer-reviewed users, CCSG funds were well leveraged. In grant Yr44,
the SMF is requesting $497,812 from the CCSG (estimated 6.6% of its budget).
In the coming grant cycle, the SMF will continue to build on its record of providing cutting-edge genomic services
to support high-impact science. Current plans include 1) continuing the development of specialized protocols
and services, including immune profiling, single-cell copy number analysis, single-cell ATAC-Seq, and single-
cell CRISPR sequencing, as well as phased exomes and whole genomes, accurate large structural variant
identification, and digital spatial profiling, and 2) expanding SMF services to include enhanced data processing.
With these measures, we will continue to provide investigators with the unique and exceptional...

## Key facts

- **NIH application ID:** 10466979
- **Project number:** 5P30CA016672-46
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** Vicki Huff
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $767,537
- **Award type:** 5
- **Project period:** 1996-08-28 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10466979

## Citation

> US National Institutes of Health, RePORTER application 10466979, 01 Sequencing and Microarray Facility (5P30CA016672-46). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10466979. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*